Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 12796550.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Butyrylcholinesterase is implicated in the pathology of AD. Selective inhibitors increase acetylcholine and improve cognitive function in animal models. In dementia with Lewy bodies, cholinergic activities are more affected than in AD. The authors report a highly significant association between temporal cortex butyrylcholinesterase activity and the rate of cognitive decline in a prospectively studied, autopsy-confirmed dementia with Lewy bodies series.
Medical subject headings
- Butyrylcholinesterase
- Cognition Disorders
- Lewy Body Disease